Sindilizumab immunotherapy is an anti-tumor drug, mainly for the treatment of Hodgkin’s lymphoma, non-squamous non-small cell lung cancer, hepatocellular carcinoma and many other serious cancers, and is a new type of drug, commonly used in the form of injection. During the treatment process, about 80% of patients may have side effects, which may lead to discomfort in the nervous system, cardiovascular system, respiratory system, gastrointestinal system, hepatobiliary system, renal and urinary system, and skin system. 1. nervous system: most patients may suffer from insomnia or drowsiness, and a few patients may suffer from anxiety, irritability, fatigue and sleepiness. 2. cardiovascular system: common conditions such as anemia, neutropenia, hypoalbuminemia, and hypocretinemia. 2, the cardiovascular system: common symptoms such as anemia, neutropenia, hypoalbuminemia, hyperglycemia, hypertension, hypotension, hypokalemia, sinus bradycardia, atrial fibrillation, ventricular extrasystole, a few patients may develop thrombocytopenia, coagulation dysfunction, myocarditis, etc.; 3, the respiratory system: common lung infections, interstitial lung disease, a few patients may develop immune-mediated pneumonia; 4, the gastrointestinal system: such as decreased appetite, abdominal pain, diarrhea, nausea 5. Hepatobiliary system: elevated aspartate aminotransferase is common, and abnormal liver function is occasionally seen; 6. Renal and urinary system: proteinuria and hematuria are common, and acute kidney injury is occasionally seen; 7. Skin system: rash and herpes zoster may appear in most patients, and vitiligo may appear in a few. In addition, abnormal electrocardiogram T waves, decreased blood cells, decreased platelet count and white blood cell count, increased γ-glutamyl transferase, increased lipase, decreased lymphocyte count and other indicators may be found during the application of this drug. Although, Sindilizumab immunotherapy has more side effects, based on the severity of some cancer patients, it is still recommended to choose to receive Sindilizumab immunotherapy when necessary in order to actively fight cancer and treat the disease.